Sagimet Biosciences INC 10-Q quarterly reports

Sagimet Biosciences Inc. reported a substantial increase in cash and cash equivalents following a $175 million underwritten offering, while also detailing progress in its clinical-stage drug development programs for acne and MASH.

Sagimet Biosciences reports a significant decrease in R&D expenses for Q1 2026, improved cash flow from investing activities, and sufficient liquidity for the next 12 months following a substantial capital raise.

Sagimet Biosciences reported a reduced net loss in Q3 2025, driven by lower R&D expenses, while advancing its denifanstat and TVB-3567 clinical programs for MASH and acne.

Sagimet Biosciences reports increased losses and cash burn in Q2 2025, alongside significant clinical progress for denifanstat in MASH and acne, and the initiation of a new Phase 1 trial for TVB-3567.

Sagimet Biosciences' Q1 2025 report highlights increased R&D spending, progress in clinical trials, and ongoing efforts to secure funding for Phase 3 trials.

Sagimet Biosciences announced its third quarter 2024 financial results, highlighted by progress in its Phase 3 clinical program for denifanstat and a Breakthrough Therapy designation from the FDA.

Sagimet Biosciences' second quarter 2024 report highlights increased R&D spending, positive clinical trial data, and a strengthened financial position.

Sagimet Biosciences reported its first quarter 2024 financial results, highlighting progress in its clinical programs and financial position.